Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ACADEMIA
ACADEMIA
- Regulatory Science Society Holds 1st Scientific Convention
September 19, 2011
- NCGM Hospital Removes Actos from List of Recommended Drugs in Diabetes Manual
September 14, 2011
- Clinical Positioning Needs to Be Clarified for Nexavar, Sutent: Prof. Naito of Kyushu Univ.
September 12, 2011
- Intensive Therapy with Rosuvastatin Effective at Inhibiting Progression of IMT: JART Study
September 12, 2011
- Apixaban Superior to Warfarin, Risk of Major Bleeding Down 30%: ESC
September 12, 2011
- 42 Nat’l Univ. Hospitals Share Drug Price Information to Reduce Purchase Costs
September 12, 2011
- NCC Aims to Become World’s Leading Early Clinical Development Center
September 12, 2011
- ”Seller’s Market” for Pharmacists Expected to Continue Over Next Few Years
September 7, 2011
- JCS Recommends Dabigatran in Patients with CHADS2 Score of 1
September 5, 2011
- Osaka Univ. Hospital to Lead Innovation to Discover Globally Competitive Drugs
September 5, 2011
- Univ. of Tokyo Hospital to Initiate PI Trial of Radical AD Treatments
September 5, 2011
- Keio Univ. to Begin PI Trials of New Drugs for Refractory Immunological Diseases in FY2012
September 5, 2011
- Generic Drugs Accounted for 23.1% of Drug Sales Volume in April-June: JGA
September 2, 2011
- National Cancer Center to Set Up Phase I Center by End of FY2011
September 1, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…